*Doheny Eye Institute, Los Angeles, CA;
†Department of Ophthalmology, David Geffen School of Medicine, UCLA, Los Angeles, CA; and
‡Carl Zeiss Meditec, Inc, Dublin, CA.
Correspondence: Hugo Y. Hsu, MD, Department of Ophthalmology, Doheny Eye Center of UCLA, David Geffen School of Medicine, UCLA, 800 Fairmount Avenue, Suite 215 Pasadena, CA 91105 (e-mail: [email protected]).
SriniVas R. Sadda; Carl Zeiss Meditec (Financial intest [F]), Optos (F, Consultant [C]), Allergan (F, C), Genentech (F, C), Alcon (C), Novartis (C), Roche (C), Regeneron (C), Bayer (C), ThromboGenics (C), Stem Cells (C), Avalanche (C). The remaining authors have no funding or conflicts of interest to disclose.